TAVI

EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis

Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years, excluding those with tricuspid valves.&nbsp; This study included low surgical risk patients with severe aortic stenosis and symptoms, 75 years or younger. Participants were randomized 1:1 to receiving TAVR or SAVR, stratified according to sex, need for new<a href="https://solaci.org/en/2024/05/17/europcr-2024-notion-2-tavi-vs-savr-randomized-study-on-low-risk-young-patients-with-severe-tricuspid-disease-or-bicuspid-stenosis/" title="Read more" >...</a>

EuroPCR 2024 | SOLVE-TAVI: Self Expanding or Balloon Expandable Valves?

This was a randomized study with 447 patients carried out to compare the 5-year evolution of TAVR using Evolut R and SAPIEN 3, as well as general anesthesia vs. conscious sedation.&nbsp; Randomization was in two stages: first valve selection and later the anesthesia technique, that is, conscious sedation vs general anesthesia. The populations were similar.<a href="https://solaci.org/en/2024/05/15/europcr-2024-solve-tavi-self-expanding-or-balloon-expandable-valves/" title="Read more" >...</a>

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

Acute Myocardial Infarction After TAVI: Retrospective Analysis of >200,000 Implants

Coronary artery disease is common among patients considered for transcatheter aortic valve implantation (TAVI). With the expansion of the indication for TAVI to a population with lower surgical risk, and therefore younger, there has been a gradual increase in the incidence of coronary events. However, there is limited data on treatment strategy and outcomes in<a href="https://solaci.org/en/2024/05/04/acute-myocardial-infarction-after-tavi-retrospective-analysis-of-200000-implants/" title="Read more" >...</a>

pacemaker marcapasos definitivo

Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study

Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation<a href="https://solaci.org/en/2024/03/20/guidewire-pacing-and-pressure-assessment-in-tavr-the-safe-tavi-study/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

Should We Treat Obstructive Coronary Artery Disease in TAVI?

Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the<a href="https://solaci.org/en/2024/02/07/should-we-treat-obstructive-coronary-artery-disease-in-tavi/" title="Read more" >...</a>

Top